Zilucoplan
Brand names: Zilbrysq · Active ingredient: Zilucoplan
In short: ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
What is Zilucoplan used for?
ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
⚠ Boxed warning (FDA's strongest warning)
ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by
Neisseria meningitidis
. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.
Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risks of delaying therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination against meningococcal bacteria in patients receiving a complement inhibitor. See
Warnings and Precautions (5.1)
for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.
Patients receiving ZILBRYSQ are at increased risk for invasive disease caused by
Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.
Because of the risk of serious meningococcal infections, ZILBRYSQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ZILBRYSQ REMS
.
Zilucoplan dosage
Vaccinate patients against meningococcal infection (serogroups A, C, W, Y, and B) according to current ACIP recommendations at least 2 weeks prior to initiation of ZILBRYSQ
.
If urgent ZILBRYSQ therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible
.
Healthcare providers who prescribe ZILBRYSQ must enroll in the ZILBRYSQ REMS
.
Before initiating ZILBRYSQ, obtain baseline lipase and amylase levels
.
The recommended dosage of ZILBRYSQ is given once daily as a subcutaneous injection and is dependent on actual body weight .
Body Weight | Once Daily Dosage | Plunger Rod Color of Prefilled Syringe
Less than 56 kg | 16.6 mg | RUBINE RED
56 kg to less than 77 kg | 23 mg | ORANGE
77 kg and above | 32.4 mg | DARK BLUE
ZILBRYSQ prefilled syringes can be stored in a refrigerator in the original carton. ZILBRYSQ can also be stored at room temperature in the original carton for up to 3 months or until the expiration date, whichever occurs first.
If stored in the refrigerator:
Before injecting, take 1 ZILBRYSQ prefilled syringe out of the refrigerator and place it on a clean, flat surface. Allow ZILBRYSQ to reach room temperature out of direct sunlight (30 to 45 minutes). Do not heat or place in microwave.
Immediately return the carton with the other prefilled syringes to the refrigerator.
If stored at room temperature:
Remove 1 ZILBRYSQ prefilled syringe from the carton.
Do not return ZILBRYSQ to the refrigerator after it has been stored at room temperature.
Visually inspect ZILBRYSQ for particulate matter and discoloration prior to administration. ZILBRYSQ is a clear to slightly opalescent, colorless solution. Do not use if the solution contains visible particles, is cloudy, or if foreign particulate matter is present. ZILBRYSQ does not contain preservatives; unused portions of drug remaining in the syringe should be discarded.
Each prefilled syringe is single-dose only.
ZILBRYSQ is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject ZILBRYSQ after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of ZILBRYSQ according to the "Instructions for Use"
.
Administer ZILBRYSQ subcutaneously into areas of the abdomen, thighs, or back of the upper arms that are not tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks. Rotate injection sites for each administration. Administration of ZILBRYSQ in the upper, outer arm should be performed by a caregiver. …
How to take Zilucoplan — instructions & advice from the label
Advise the patients and/or caregivers to read FDA-approved patient labeling (Medication Guide and Instructions for Use)
.
Serious Meningococcal Infection
Advise patients of the risk of serious meningococcal infection
. Inform patients of the need to complete or update meningococcal vaccinations at least 2 weeks prior to receiving the first dose of ZILBRYSQ or receive antibacterial drug prophylaxis if ZILBRYSQ treatment must be initiated immediately and they have not been previously vaccinated. Inform patients of the requirement to be revaccinated according to current ACIP recommendations for meningococcal infection while on ZILBRYSQ therapy.
Inform patients that vaccination may not prevent serious meningococcal infection and to seek immediate medical attention if the following signs or symptoms occur:
fever
fever and a rash
fever with high heart rate
headache with nausea or vomiting
headache and a fever
headache with a stiff neck or stiff back
confusion
muscle aches with flu-like symptoms
eyes sensitive to light
Inform patients that they will be given a Patient Safety Card for ZILBRYSQ that they should carry with them at all times and for 2 months following treatment with …
Warnings & precautions
Do not take this medicine if: ZILBRYSQ is contraindicated for initiation in patients with unresolved serious
Neisseria meningitidisinfection
.
ZILBRYSQ, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of ZILBRYSQ treatment is contraindicated in patients with unresolved serious
Neisseria meningitidisinfection.
Complete or update meningococcal vaccination (for serogroups A, C, W, Y and B) at least 2 weeks prior to administration of the first dose of ZILBRYSQ, according to current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of ZILBRYSQ therapy. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information.
If urgent ZILBRYSQ therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including ZILBRYSQ. …
Zilucoplan side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Serious Meningococcal Infections
Other Infections
Pancreatitis and Other Pancreatic Conditions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 212 patients were treated with ZILBRYSQ 0.3 mg/kg in clinical studies in gMG. Of these, 137 patients were exposed for at least 6 months, and 87 were exposed for at least 1 year.
In a placebo-controlled study (Study 1) in patients with gMG, 86 patients received ZILBRYSQ 0.3 mg/kg
. Of these 86 patients, approximately 61% were female, 77% were White, 8% were Asian, and 8% were of Hispanic or Latino ethnicity. The mean age at study entry was 52.6 years (range 21 to 75 years). Table 2 summarizes the adverse reactions reported in at least 5% of patients treated with ZILBRYSQ and more frequently than placebo. The most common adverse reactions (reported in at least 10% of patients treated with ZILBRYSQ) were injection site reactions, upper respiratory tract infections, and diarrhea. …
About this medicine
Zilucoplan, a complement inhibitor, is a 15 amino-acid, synthetic macrocyclic peptide.
The molecular formula of zilucoplan is C
172H
278N
24O
55in free acid form and its molecular weight is 3562.23 Daltons (free acid form).
The chemical name for zilucoplan sodium is: acetyl‐[L-lysyl
1-L-valyl
2-L-glutamyl
3-L-arginyl
4-L phenylalanyl
5-L aspartyl
6]-
N-methyl L-aspartyl
7-L tert-leucyl
8-L tyrosyl
9-L-7-azatryptophyl
10-L glutamyl
11-L-tyrosyl
12-L prolyl
13-L cyclohexylglycyl
14-[L-lysyl
15,
N
ε-palmitoyl-γ-L-glutamyl-(1-amino-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72-tetracosaoxapentaheptacontan-75-oyl)], cyclic (Lactam 1-6), tetra sodium.
The primary structure for zilucoplan sodium is shown below:
ZILBRYSQ injection is a sterile, clear to slightly opalescent, colorless, preservative-free, buffered solution of zilucoplan (as zilucoplan sodium) for subcutaneous injection, in single-dose prefilled syringes. The solution pH is between 6.5 and 7.5. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9f1d53d6-e495-4a3a-8bb9-680a15d25034. Read the full official label on DailyMed.